From Slopes to Science: Lindsey Vonn to Champion Antibody Education

NEW HAVEN, Conn. – January 22, 2026 – World champion skier Lindsey Vonn, in the midst of a remarkable comeback aimed at the 2026 Winter Olympics, is embarking on a new challenge: demystifying antibody science for the American public. Biopharmaceutical firm Invivyd, Inc. announced today a partnership with the decorated athlete to spearhead a national educational campaign focused on the immune system and disease prevention.

The collaboration will see Vonn become the public face of an initiative launching in spring 2026, strategically timed to follow her highly anticipated Olympic season. The campaign aims to transform complex immunology into accessible wellness knowledge, positioning antibody science as a key component of modern health strategies.

A Comeback with a Cause

Lindsey Vonn's career is a testament to resilience. After retiring in 2019, the ski racing icon—who holds 84 World Cup victories and is the only American woman to win Olympic downhill gold—mounted one of the most inspiring comebacks in sports. Returning to competition in 2024 after a knee replacement, she defied expectations by rejoining the U.S. Ski Team and, just last month, qualified for the Downhill event at the Milan Cortina 2026 Olympic Winter Games.

This narrative of peak physical performance and meticulous self-care forms the foundation of her partnership with Invivyd. Vonn's credibility is rooted not just in her athletic prowess but in her deep understanding of what it takes to maintain a body at its best. "My athletic career has been about maximizing the potential of what my body can do: training hard, recovering smart, and learning to listen when it tells me something. My entire job is to take care of my body — I can’t afford to get sick,” Vonn stated in the announcement.

By leveraging her personal journey, the campaign seeks to connect with an audience that might otherwise find scientific topics intimidating. Her role transcends that of a typical celebrity endorser, positioning her as an advocate whose life experience directly aligns with the message of proactive health management. "That is why Invivyd’s mission to advance antibody science resonates with me, and I’m excited to collaborate with them on this important educational initiative," Vonn added.

Invivyd's Strategic Pivot Beyond COVID-19

For Invivyd, this partnership marks a significant strategic maneuver to broaden its corporate identity. The company first gained prominence for its work on SARS-CoV-2, deploying its proprietary INVYMAB™ platform to rapidly develop antibody therapies against the evolving virus. In March 2024, it received Emergency Use Authorization from the FDA for PEMGARDA, a monoclonal antibody for pre-exposure prophylaxis (PrEP) of COVID-19. Its pipeline also includes VYD2311, another antibody candidate currently in Phase 3 trials for preventing symptomatic COVID-19.

However, the company's ambitions extend far beyond a single virus. With a stated mission to deliver protection from a range of serious viral diseases, Invivyd is actively expanding its pipeline. The company is advancing VBY329, an antibody candidate for Respiratory Syncytial Virus (RSV), toward clinical trials and has early discovery programs for both measles and influenza.

This partnership with a globally recognized athlete like Vonn is a calculated move to reframe the company's narrative from a specialized COVID-19 response firm to a broader leader in antibody-based disease prevention. The campaign aims to build public awareness and understanding of antibodies as a versatile tool for health, a strategy that could cultivate a market for its future products. This educational push is backed by a solid financial footing; Invivyd secured over $200 million in capital in the second half of 2025 and reported a 25% year-over-year increase in net product revenue for PEMGARDA in the last quarter.

Demystifying the Immune System

The campaign's central challenge lies in bridging the gap between complex science and public understanding. In an era of information overload and widespread health misinformation, communicating nuanced topics like immunology effectively is paramount. The collaboration aims to cut through the noise by using a trusted voice to deliver a clear message.

"Americans deserve more information and choices about how to stay healthy," said Marc Elia, Chairman of Invivyd’s Board of Directors. "Partnering with Lindsey Vonn will expand awareness of antibody science in a way that is relatable, understandable, and trustworthy."

At its core, the initiative will educate the public about antibodies—proteins produced by the immune system that are critical for identifying and neutralizing pathogens like viruses. Invivyd's platform, INVYMAB™, is designed to engineer these antibodies to be more potent and durable than those produced naturally, offering a potential shield against infection. By explaining this science in the context of Vonn's quest for peak health, the campaign hopes to empower individuals with knowledge. As Vonn put it, "This movement is about helping everyone understand the potential to enhance their immune system, including antibody protection. Health shouldn’t be confusing or intimidating. It should be empowering."

A Competitive Field of Prevention

Invivyd's public-facing strategy arrives at a critical time in a highly competitive biopharmaceutical landscape. The market for infectious disease prevention is crowded and dynamic. In the COVID-19 space, the constant evolution of viral variants has posed a significant challenge for antibody therapies, with some earlier products losing their authorization as new strains emerged.

Beyond COVID-19, the company faces established and emerging players in the RSV market, where its VBY329 candidate will compete against other antibodies and new vaccines. For diseases like measles and influenza, the primary prevention tools remain highly effective vaccines that have been public health mainstays for decades.

By investing in a high-profile educational campaign, Invivyd is not just selling a product; it is building a brand around a concept—the power of engineered antibodies. The timing, set for after the 2026 Olympics, is designed to capitalize on the heightened visibility Vonn will have on the world stage. This strategic blend of athletic triumph and scientific advocacy aims to differentiate Invivyd's approach, creating public familiarity and trust in antibody technology as a cornerstone of future wellness and disease prevention strategies.